DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Ingrezza is a drug marketed by Neurocrine and is included in one NDA. There are nineteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and thirty-five patent family members in thirty countries.
The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
Ingrezza was eligible for patent challenges on April 11, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 18, 2038. This may change due to patent challenges or generic licensing.
There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for INGREZZA
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||26|
|Drug Prices:||Drug price information for INGREZZA|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for INGREZZA|
|What excipients (inactive ingredients) are in INGREZZA?||INGREZZA excipients list|
|DailyMed Link:||INGREZZA at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for INGREZZA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for INGREZZA
Identify potential brand extensions & 505(b)(2) entrants
|Neurocrine Biosciences||Phase 2|
Pharmacology for INGREZZA
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2017075340||⤷ Free Forever Trial|
|Australia||2017395702||⤷ Free Forever Trial|
|Canada||3002074||⤷ Free Forever Trial|
|Japan||2020505408||⤷ Free Forever Trial|
|South Korea||20180075591||⤷ Free Forever Trial|
|Taiwan||202021585||⤷ Free Forever Trial|
|Taiwan||202114675||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|